# Development of Therapeutic Products for Antibiotic Resistant Bacteria

> **NIH NIH N01** · CRESTONE, INC. · 2023 · $2,665,864

## Abstract

To support the advanced development of a promising candidate therapeutic for NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

## Key facts

- **NIH application ID:** 10919149
- **Project number:** 75N93020C00020-P00008-9999-1
- **Recipient organization:** CRESTONE, INC.
- **Principal Investigator:** URS OCHSNER
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $2,665,864
- **Award type:** —
- **Project period:** 2020-07-01 → 2025-07-09

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10919149

## Citation

> US National Institutes of Health, RePORTER application 10919149, Development of Therapeutic Products for Antibiotic Resistant Bacteria (75N93020C00020-P00008-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10919149. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*